Peptide Knowledge Base · GH-axis

CJC-1295: what it is, what the evidence says, and its real status

The legal GH-axis route is Sermorelin.

Can you actually get it?

Plain-English verdict: Education only.

Regulatory status: Nomination withdrawn · in no FDA category.

How does CJC-1295 work?

A long-acting GHRH analog that stimulates pituitary growth-hormone release, often combined with a GH secretagogue like Ipamorelin.

What it does — and what it does not do

What it does: Studied as a GH-axis stimulator for recovery and body-composition interest.

What it does not do: It cannot be legally compounded in the US, and Peptós.LIFE does not offer it, it is education only.

How honest is the evidence?

Evidence grade C — Mixed / early human evidence.

modest human GHRH-analog data; long-acting (DAC) variants less characterized

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Long-term safety of the long-acting (DAC) form is poorly characterized in humans.

WADA status: Banned (S2).

Who should not take it

Banned in tested sport (WADA S2); not compoundable in the US. Not a substitute for evaluated GH-axis care.

Sources

GHRH-analog clinical literature · FDA compounding Category 2 list (Sept 2023) · FDA bulk drug substances nominated but withdrawn table (content current 04/22/2026)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 16, 2026 · Peptós.LIFE · Not medical advice.